FOLR1 and ovarian carcinoma: In a phase III, open-label, 11-center study conducted between March 2018 and April 2020, pafolacianine and near-infrared imaging were used to identify residual cancer tissue in 33% of patients with FRα-positive ovarian cancers undergoing tumor resection.